Health Care & Life Sciences » Medical Equipment & Supplies | NanoVibronix Inc.

NanoVibronix Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
211.00
203.00
147.00
229.00
239.00
318
Cost of Goods Sold (COGS) incl. D&A
91.00
93.00
49.00
88.00
88.00
158
Gross Income
120.00
110.00
98.00
141.00
151.00
160
SG&A Expense
1,230.00
1,321.00
1,522.00
2,457.00
3,242.00
4,463
EBIT
1,110.00
1,211.00
1,424.00
2,316.00
3,091.00
4,303
Unusual Expense
77.00
138.00
962.00
383.00
549.00
-
Non Operating Income/Expense
57.00
8.00
-
-
-
-
Interest Expense
710.00
1,257.00
470.00
15.00
1,287.00
-
Pretax Income
1,954.00
2,598.00
2,856.00
2,714.00
4,927.00
4,281
Income Tax
35.00
49.00
28.00
117.00
38.00
127
Consolidated Net Income
1,989.00
2,647.00
2,884.00
2,831.00
5,806.00
4,154
Net Income
1,989.00
2,647.00
2,884.00
2,831.00
5,806.00
4,154
Net Income After Extraordinaries
1,989.00
2,647.00
2,884.00
2,831.00
5,806.00
4,154
Net Income Available to Common
1,989.00
2,647.00
2,884.00
2,831.00
5,806.00
4,154
EPS (Basic)
0.44
0.58
1.46
0.62
1.17
0.64
Basic Shares Outstanding
4,562.60
4,562.60
1,978.40
4,578.50
4,964.10
6,448.30
EPS (Diluted)
0.44
0.58
1.46
0.62
1.17
0.64
Diluted Shares Outstanding
4,562.60
4,562.60
1,978.40
4,578.50
4,964.10
6,448.30
EBITDA
1,100.00
1,202.00
1,415.00
2,309.00
3,086.00
4,297
Other After Tax Income (Expense)
-
-
-
-
841.00
-

About NanoVibronix

View Profile
Address
525 Executive Boulevard
New york New York 10523
United States
Employees -
Website http://www.nanovibronix.com
Updated 07/08/2019
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices that target wound healing, and pain therapy and can be administered at home, without the assistance of medical professionals. Its products include WoundShield, PainShield, and UroShield. It operates through the following geographical segments: United States, Israel, United Kingdom, European Union, India, and Other.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.